Lv31
280 积分 2021-03-11 加入
血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则
4小时前
已完结
Delay differential equation (DDE) modeling of CAR-T cellular kinetics: Application to BCMA-targeted (Ide-cel, Orva-cel) and CD19-targeted (Lisocel) therapies
8天前
已完结
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
9天前
已完结
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
11天前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
11天前
已完结
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
11天前
已完结
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
11天前
已完结
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
11天前
已完结
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
11天前
已完结
Cytogenetics in the management of mature B-cell non-Hodgkin lymphomas: Guidelines from the Groupe Francophone de Cytogénétique Hematologique (GFCH)
17天前
已完结
皖公网安备34019202002308
